Opinion|Podcasts|August 31, 2023

Ethical AI Practices

In this Pharm Exec Podcast episode, Gerald Kierce, co founder and CEO of Trustible, and Andrew Camino Chung, the company's CTO and co founder, delve into the realm of artificial intelligence, discussing Trustible's mission and its pioneering efforts to ensure ethical AI use, particularly in the pharmaceutical industry, and how it navigates complex AI regulations across the globe.

Gerald Kierce, co founder and CEO of Trustible and Andrew Gamino-Cheong, the company's CTO and co founder, discuss their company mission and its pioneering efforts to ensure ethical AI use particularly in the pharmaceutical industry, and how it navigates complex AI regulations across the globe. They also explore the delicate balance between AI transparency and proprietary protection, their proactive approach towards AI ethics, and the strategic roadmap for the future.


About the speakers

Gerald Kierce is the Co-Founder & CEO of Trustible – a leading technology provider of responsible AI governance. Its software platform enables AI and compliance teams to scale their AI Governance programs to help build trust, manage risk, and comply with AI regulations.

Prior to founding Trustible, Gerald was an executive at FiscalNote (NYSE: NOTE) where he spent nearly a decade at the company across a variety of roles including VP & General Manager of their AI Solutions division, Corporate Development, Chief of Staff, Product Marketing, and Customer Success. FiscalNote was the most recent DC-based company to go public in the New York Stock Exchange in August of 2022. He is originally from San Juan, Puerto Rico.

Andrew Gamino-Cheong is the Co-Founder & CTO of Trustible – a leading technology provider of responsible AI governance. Its software platform enables AI and compliance teams to scale their AI Governance programs to help build trust, manage risk, and comply with AI regulations.

Andrew has spent his career working at the intersection of policy and AI. Prior to founding Trustible, Andrew was a machine learning engineering tech led at FiscalNote (NYSE: NOTE), a DC based policy information services company, where he built AI systems to help organizations better understand and map regulatory risks, applying AI to the policy landscape. Now, at Trustible, he's flipped the script and is working to apply policy to the AI landscape. Andrew has a Bachelors degree from Georgetown University, where he double majored in Computer Science and Government, and a Masters in Computer Science from the University of Maryland College Park.


About the Pharm Exec Podcast

The editors of Pharmaceutical Executivebring you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.

Listen to this podcast on SoundCloudSpotifyGoogle Podcasts, or Apple Podcasts.


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Pharmaceutical Executive daily
FDA approves Kerendia as the first new treatment for kidney disease in type 1 diabetes in decades, Novo, Roche, and Aethlon Medical strike major deals and mergers with Orbis Medicines, Dualitas Therapeutics, and North Immunology, and Thani Jambulingam of Saint Joseph's University examines the fight to control the GLP-1 patient journey.
Pharmaceutical executive daily
GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership with Cheplapharm, Stewart Gandolf discusses why pharma marketing now has to write for both people and AI, and Dr. Elena Christofides explains why cortisol dysregulation may be the hidden reason some diabetes patients fail to respond to incretin therapies.